Literature DB >> 18242856

Peripheral cannabinoids attenuate carcinoma-induced nociception in mice.

Andre V Guerrero1, Phuong Quang, Nusi Dekker, Richard C K Jordan, Brian L Schmidt.   

Abstract

We investigated the cannabinoid receptor (CBr) agonists Win55,212-2 (non-selective) and AM1241 (CBr2 selective) and the peripheral receptor (CBr1) in carcinoma-induced pain using a mouse model. Tumors were induced in the hind paw of female mice by local injection of a human oral squamous cell carcinoma (SCC). Significant pain, as indicated by reduction in withdrawal thresholds in response to mechanical stimulation, began at 4 days after SCC inoculation and lasted to 18 days. Local administration of Win55,212-2 (10 mg/kg) and AM1241 (10 mg/kg) significantly elevated withdrawal thresholds, indicating an antinociceptive effect. Ipsilateral expression of CBr1 protein in L5 DRG was significantly upregulated compared to ipsilateral L4 DRG and in normal tissue. These findings support the suggestion that cannabinoids are capable of producing antinociception in carcinoma-induced pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18242856      PMCID: PMC2771220          DOI: 10.1016/j.neulet.2007.12.053

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  44 in total

Review 1.  Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors.

Authors:  R G Pertwee
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

Review 2.  Breakthrough pain in cancer patients: pathophysiology and treatment.

Authors:  S Mercadante; E Arcuri
Journal:  Cancer Treat Rev       Date:  1998-12       Impact factor: 12.111

3.  Cannabinoid receptors undergo axonal flow in sensory nerves.

Authors:  A G Hohmann; M Herkenham
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

4.  Management of cancer pain.

Authors:  R K Portenoy; P Lesage
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

Review 5.  Cannabinoids as potential new analgesics.

Authors:  J A Fuentes; M Ruiz-Gayo; J Manzanares; G Vela; I Reche; J Corchero
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

6.  Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors.

Authors:  Jennelle Durnett Richardson; Sonja Kilo; Kenneth M Hargreaves
Journal:  Pain       Date:  1998-03       Impact factor: 6.961

7.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Authors:  A R Schatz; M Lee; R B Condie; J T Pulaski; N E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  1997-02       Impact factor: 4.219

8.  Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain.

Authors:  Jianren Mao; Donald D Price; David J Mayer
Journal:  Pain       Date:  1995-06       Impact factor: 6.961

9.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

10.  Control of pain initiation by endogenous cannabinoids.

Authors:  A Calignano; G La Rana; A Giuffrida; D Piomelli
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

View more
  16 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

2.  Cannabinoids attenuate cancer pain and proliferation in a mouse model.

Authors:  Negin Saghafi; David K Lam; Brian L Schmidt
Journal:  Neurosci Lett       Date:  2010-11-19       Impact factor: 3.046

3.  CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.

Authors:  Iryna A Khasabova; James Gielissen; Anisha Chandiramani; Catherine Harding-Rose; Desiree Abu Odeh; Donald A Simone; Virginia S Seybold
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.

Authors:  V Curto-Reyes; S Llames; A Hidalgo; L Menéndez; A Baamonde
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

5.  Combined antiproliferative effects of the aminoalkylindole WIN55,212-2 and radiation in breast cancer cells.

Authors:  Sean M Emery; Moureq R Alotaibi; Qing Tao; Dana E Selley; Aron H Lichtman; David A Gewirtz
Journal:  J Pharmacol Exp Ther       Date:  2013-11-20       Impact factor: 4.030

Review 6.  The analgesic potential of cannabinoids.

Authors:  Jaseena Elikkottil; Jaseena Elikottil; Pankaj Gupta; Kalpna Gupta
Journal:  J Opioid Manag       Date:  2009 Nov-Dec

7.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

8.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

9.  The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms.

Authors:  Carl Potenzieri; Catherine Harding-Rose; Donald A Simone
Journal:  Brain Res       Date:  2008-04-06       Impact factor: 3.252

10.  A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.

Authors:  Iryna A Khasabova; Sergey G Khasabov; Catherine Harding-Rose; Lia G Coicou; Bryan A Seybold; Amy E Lindberg; Christopher D Steevens; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.